Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Remington Davis Inc

Neither a doctor nor a teaching hospital

Research payments

$3,202,852

275 payments

Through program year 2025, Remington Davis Inc is reported as receiving $3,202,852 in research payments, across 275 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,115,390 80
2024 Research $776,121 65
2023 Research $158,448 8
2022 Research $122,447 8
2021 Research $229,254 61
2020 Research $672,684 44
2019 Research $128,508 9

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,490,259 45 payments
  2. Moderna TX, Inc. $617,649 61 payments
  3. Novartis Pharmaceuticals Corporation $393,426 8 payments
  4. Ironwood Pharmaceuticals, Inc $317,338 51 payments
  5. GlaxoSmithKline, LLC. $181,579 50 payments
  6. Braintree Laboratories, Inc. $97,445 14 payments
  7. Amgen Inc. $50,372 3 payments
  8. Boehringer Ingelheim Canada Ltd.Ltee $27,858 36 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $25,426 6 payments
  10. Mylan Specialty L.P. $1,500 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A 24 Week Multicenter Double Blind Placebo Controlled Dose Ranging Study to Investigate the Efficacy and Safety of Oral Qbw251 in COPD Patients on Triple Therapy (Laba/Lama/Ics) $384,249 3 payments
  2. A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis $380,549 56 payments
  3. a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure $248,269 2 payments
  4. A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) $247,436 8 payments
  5. a phase III,randomised,double blind,placebo controlled,event driven study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure $237,669 1 payment
  6. A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Mrna-1403, A Multivalent Candidate Vaccine to Prevent Norovirus Acute Gastroenteritis in Adults 18 Years of Age $237,099 5 payments
  7. C3718-302 $216,899 34 payments
  8. A Phase IIa Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi-Centre Study to Evaluate the Efficacy and Safety of AZD4831, for 12-24 Weeks, in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) $147,808 3 payments
  9. A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Para $139,395 47 payments
  10. A Phase II Randomized Double-blind Placebo controlled Study to Assess the Efficacy Safety and Tolerability of MEDI3506 in Participants with Moderate to Severe Chronic Obstructive Pulmonary Disease and Chronic Bronchitis FRONTIER 4 $128,705 8 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record